Navigation Links
Vetter announces completion of its Schuetzenstrasse multi-functional building for Development Service and state-of-the-art Information Technology
Date:1/31/2016

Vetter, a leading contract development and manufacturing organization (CDMO) committed to providing customers with the manufacture of high quality drug products, announced today that following approximately two years of construction, its Schuetzenstrasse multi-functional building has been completed on schedule and departments critical to its operation have started to move in. The 29 million Euro investment in the new building is part of a 300 million euro total investment strategy announced by the company in September 2015 for further development to its manufacturing sites, and to make available additional manufacturing capacities. The Schuetzenstrasse building itself is in response to an increase in demand by customers for support in drug development, as well as the need for enhanced IT systems to meet future customer and regulatory requirements already being seen today.

Vetter supports many of the world’s leading pharmaceutical and biotech companies from development through to manufacturing and final packaging of their drug products. The continued demand by its large and small customers for enhanced drug development services, as well as the need for ever-more future-oriented sophisticated IT systems to protect their data, created the need for the new 8,500 sqm (91,500 sq. ft.), six-story building. It contains non-cGMP laboratories for development support, laboratory space for microbiological analysis, office workplaces for Vetter Development Service and IT as well as in its core, a data processing center with enhanced security systems, including a safety cell that protects technology and data from external physical hazards in the event of an emergency.

"With the installation of these future-oriented IT systems, we are early-on addressing the need for increased connectivity between customers and their manufacturing partners, like Vetter, to efficiently share and store data without concern for its safety,” said Oliver Albrecht, a Vetter Managing Director. “The new building is further evidence that Vetter is well-prepared to meet present and future industry challenges and requirements." Managing Director Thomas Otto added, "With this building, we are meeting the growing demand of our customers for drug development support. The investments in both our Development Service capabilities and our IT system reflect two of the core aspects of Vetter’s orientation as an innovative Contract Development and Manufacturing Organization."

Continued positive company development
2015 was another successful year economically for the company as evidenced by a growing customer demand for projects in clinical development, commercial manufacturing, and final packaging, a result of Vetter’s high quality and safety standards. Thus, the CDMO was able to increase sales by approximately 10 percent. Currently, the company employs around 3,600 people at its German, US, and Asian locations.

The year was also particularly eventful for Vetter. The CDMO supported nine drug approvals of its customers, e.g. within the North American, European and Japanese markets. In the third quarter, Vetter opened a new subsidiary in Tokyo, Japan to complement the Singapore operating branch created in 2014. A few weeks earlier, the company launched Vetter-Ject®, a novel closure system for prefilled syringes for use with highly-sensitive compounds such as biologics.

About Vetter
Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO’s extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of customer product approvals for novel (bio-)pharmaceutical compounds. In 2014, Vetter began operating a branch in Singapore, and in 2015, a subsidiary in Tokyo, Japan, to increase the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit http://www.vetter-pharma.com.

Contact
Vetter Pharma International GmbH
Oskar Gold
Senior Vice President Key Account Management,
Marketing / Corporate Communications
Eywiesenstrasse 5
88212 Ravensburg
Phone: +49 (0)751-3700-3729
E-mail: PRnews(at)vetter-pharma(dot)com

Read the full story at http://www.prweb.com/releases/2016/01/prweb13190008.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vetter Offers a Sterile Water-for-injection Solution with 5 Years Stability Data
2. Columbia Care Announces Opening of Suffolk County Medical Marijuana Dispensary
3. IDEXX Laboratories Announces Fourth Quarter and Full Year 2015 Results
4. Innovative Med Concepts Announces Receipt of FDA Fast Track Designation for IMC-1, a Novel Treatment for Fibromyalgia
5. Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine
6. MMS Holdings Inc. Announces Expansion of Asia Operations in Hyderabad, India
7. Amarantus Announces $1M Investment
8. MD Biosciences Announces Launch of Its Onco-Immunology Suite of Preclinical Services
9. Software Provider iLab Solutions Announces New Addition to Product Lineup
10. Bioclinica Announces Post-Approval Research Service
11. Halozyme Announces Closing Of $150 Million Royalty-Backed Debt Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2018)... ... 23, 2018 , ... LabRoots , the leading provider ... world, will host the 4th Annual Microbiology and Immunology Virtual Event September 12-13. ... various research areas including medicine, agriculture, and space. , During the free, ...
(Date:8/23/2018)... ... 2018 , ... Crucial Data Solutions, Inc. announces the release ... fully-featured app for electronic data capture (EDC) and electronic participant reported outcomes (ePRO) ... of the market share for mobile devices worldwide; in turn, this enables more ...
(Date:8/21/2018)... (PRWEB) , ... August 21, ... ... a software company specializing in medical device compliance and commercialization, has just ... Cockpit® platform. , Written and presented by Dr. Mario Kossmann, ESEP at ...
(Date:8/17/2018)... Fla. (PRWEB) , ... August 16, 2018 , ... The ... when Astro Pak acquired Chemko Technical Services in 2016. Chemko had a well established ... supporting on-site work at KSC on projects such as the ongoing work at the ...
Breaking Biology Technology:
(Date:9/12/2018)... ... 12, 2018 , ... Captiva Spine, Inc., which designs, manufactures ... 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market TowerLOX-EXT® ... TowerLOX-EXT MIS Extended Tab Pedicle Screws provide the narrow insertion of an extended ...
(Date:8/31/2018)... ... 2018 , ... R3 Stem Cell, the nation's leader in ... The freezers are very convenient for practices to maintain regenerative biologics on hand ... and umbilical cord tissue. They are stored at -80 degrees Celsius, which keeps ...
(Date:8/29/2018)... ... August 28, 2018 , ... Today, Bright Computing ... Data In Science Technologies has implemented Bright Cluster Manager at the HudsonAlpha Institute ... non-profit genomics and genetics research institute located in Huntsville, Ala. Its mission is ...
Breaking Biology News(10 mins):